Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 2/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PTGES | O14684 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436026 | 0.88 | NR1H4 (0.51) | LTB4RLTB4R2CYP2C9MEN1KMT2A | |
| SCHEMBL2306116 | 0.84 | AKR1C3 (0.49) | MEN1KMT2ALMNAHPGDFFAR4 | |
| SCHEMBL2306118 | 0.84 | AKR1C3 (0.49) | MEN1KMT2ALMNAHPGDFFAR4 | |
| SCHEMBL2301696 | 0.82 | NR1H4 (0.47) | MEN1KMT2ALMNAHPGDFFAR4 | |
| SCHEMBL2301698 | 0.82 | NR1H4 (0.47) | MEN1KMT2ALMNAHPGDFFAR4 | |
| SCHEMBL2434019 | 0.79 | NR1H4 (0.52) | CYP2C9MEN1KMT2ALMNAHPGD | |
| SCHEMBL2434020 | 0.79 | NR1H4 (0.52) | CYP2C9MEN1KMT2ALMNAHPGD | |
| SCHEMBL2436007 | 0.79 | NR1H4 (0.52) | CYP2C9MEN1KMT2ALMNAHPGD | |
| SCHEMBL2436006 | 0.79 | NR1H4 (0.52) | CYP2C9MEN1KMT2ALMNAHPGD | |
| SCHEMBL13221558 | 0.79 | NR1H4 (0.52) | CYP2C9MEN1KMT2ALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2690095-A1 | Aryl gpr120 receptor agonists and uses thereof | Camabay Therapeutics, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2582674-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2367793-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8309600-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8299117-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2514745-A1 | GPR120 receptor agonists and uses thereof | Metabolex Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2367793-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2350016-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | LTB4R 584/4885LTB4R2 428/4885PPARG 39/4885 |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | LTB4R 584/4885LTB4R2 428/4885PPARG 39/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | LTB4R 584/4885LTB4R2 428/4885PPARG 39/4885 |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | LTB4R 584/4885LTB4R2 428/4885PPARG 39/4885 |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | LTB4R 584/4885LTB4R2 428/4885PPARG 39/4885 |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | LTB4R 537/4885LTB4R2 406/4885PPARG 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.